Hackensack, N.J. (December 6, 2012) Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.
"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."
ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.
"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.
The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made i
|Contact: Amy Leahing|
John Theurer Cancer Center